<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30111989</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1537-744X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2018</Volume>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>TheScientificWorldJournal</Title>
          <ISOAbbreviation>ScientificWorldJournal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Notch Pathway in Breast Cancer Progression.</ArticleTitle>
        <Pagination>
          <StartPage>2415489</StartPage>
          <MedlinePgn>2415489</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2415489</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2018/2415489</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Notch signaling pathway is a vital parameter of the mammalian vascular system. In this review, the authors summarize the current knowledge about the impact of the Notch signaling pathway in breast cancer progression and the therapeutic role of Notch's inhibition.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The available literature in MEDLINE, PubMed, and Scopus, regarding the role of the Notch pathway in breast cancer progression was searched for related articles from about 1973 to 2017 including terms such as "Notch," "Breast Cancer," and "Angiogenesis." <i>Results</i>. Notch signaling controls the differentiation of breast epithelial cells during normal development. Studies confirm that the Notch pathway has a major participation in breast cancer progression through overexpression and/or abnormal genetic type expression of the notch receptors and ligands that determine angiogenesis. The cross-talk of Notch and estrogens, the effect of Notch in breast cancer stem cells formation, and the dependable Notch overexpression during breast tumorigenesis have been studied enough and undoubtedly linked to breast cancer development. The already applied therapeutic inhibition of Notch for breast cancer can drastically change the course of the disease.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Current data prove that Notch pathway has a major participation and multiple roles during breast tumor progression. Inhibition of Notch receptors and ligands provides innovative therapeutic results and could become the therapy of choice in the next few years, even though further research is needed to reach safe conclusions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kontomanolis</LastName>
            <ForeName>Emmanuel N</ForeName>
            <Initials>EN</Initials>
            <Identifier Source="ORCID">0000-0003-3466-3948</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Democritus University of Thrace, 681 00 Alexandroupolis, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kalagasidou</LastName>
            <ForeName>Sofia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Bodosakio General Hospital of Ptolemaida, 502 00 Ptolemaida, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pouliliou</LastName>
            <ForeName>Stamatia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiotherapy/Oncology, Democritus University of Thrace, 681 00 Alexandroupolis, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anthoulaki</LastName>
            <ForeName>Xanthoula</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Democritus University of Thrace, 681 00 Alexandroupolis, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Georgiou</LastName>
            <ForeName>Nikolaos</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Stoke Mandeville &amp; Wycombe General Hospital, Buckinghamshire NHS Trust, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papamanolis</LastName>
            <ForeName>Valentinos</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, General Hospital of Korinthos, 201 00 Korinthos, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fasoulakis</LastName>
            <ForeName>Zacharias N</ForeName>
            <Initials>ZN</Initials>
            <Identifier Source="ORCID">0000-0003-0216-3420</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Democritus University of Thrace, 681 00 Alexandroupolis, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>ScientificWorldJournal</MedlineTA>
        <NlmUniqueID>101131163</NlmUniqueID>
        <ISSNLinking>1537-744X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30111989</ArticleId>
        <ArticleId IdType="pmc">PMC6077551</ArticleId>
        <ArticleId IdType="doi">10.1155/2018/2415489</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics &amp; Gynecology. 2017;130(1):e1–e16. doi: 10.1097/AOG.0000000000002158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/AOG.0000000000002158</ArticleId>
            <ArticleId IdType="pubmed">28644335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reedijk M.  Notch Signaling in Embryology and Cancer. Vol. 727. New York, NY: Springer US; 2012. Notch Signaling and Breast Cancer; pp. 241–257. (Advances in Experimental Medicine and Biology).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4614-0899-4_18</ArticleId>
            <ArticleId IdType="pubmed">22399352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7–30. doi: 10.3322/caac.21442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21442</ArticleId>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuckey A., Febbraro T., Laprise J., Wilbur J. S., Lopes V., Robison K. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals. American Journal of Clinical Oncology. 2016;39(4):363–367. doi: 10.1097/COC.0000000000000073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/COC.0000000000000073</ArticleId>
            <ArticleId IdType="pubmed">24710121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stankov A., Bargallo-Rocha J. E., Silvio A. Ñ., Ramirez M. T., Stankova-Ninova K., Meneses-Garcia A. Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico. ISRN Oncology. 2012;2012:1–7. doi: 10.5402/2012/825258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5402/2012/825258</ArticleId>
            <ArticleId IdType="pmc">PMC3399427</ArticleId>
            <ArticleId IdType="pubmed">22830047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell R. A., McDermott H., Fancher T. L., Green M. J., Day F. C., Wilkes M. S. Impact of a Randomized Controlled Educational Trial to Improve Physician Practice Behaviors Around Screening for Inherited Breast Cancer. Journal of General Internal Medicine. 2015;30(3):334–341. doi: 10.1007/s11606-014-3113-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11606-014-3113-5</ArticleId>
            <ArticleId IdType="pmc">PMC4351290</ArticleId>
            <ArticleId IdType="pubmed">25451990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braithwaite D., Miglioretti D. L., Zhu W., et al.  Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Internal Medicine. 2018;178(4):p. 494. doi: 10.1001/jamainternmed.2017.8642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2017.8642</ArticleId>
            <ArticleId IdType="pmc">PMC5876845</ArticleId>
            <ArticleId IdType="pubmed">29435563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuckey A. Breast Cancer. Clinical Obstetrics and Gynecology. 2011;54(1):96–102. doi: 10.1097/GRF.0b013e3182080056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/GRF.0b013e3182080056</ArticleId>
            <ArticleId IdType="pubmed">21278508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamińska M., Ciszewski T., Łopacka-Szatan K., Miotła P., Starosławska E. Breast cancer risk factors. Przegląd Menopauzalny. 2015;14(3):196–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4612558</ArticleId>
            <ArticleId IdType="pubmed">26528110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamińska M., Ciszewski T., Łopacka-Szatan K., Miotła P., Starosławska E. Breast cancer risk factors. Menopausal Review. 2015;3:196–202. doi: 10.5114/pm.2015.54346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/pm.2015.54346</ArticleId>
            <ArticleId IdType="pmc">PMC4612558</ArticleId>
            <ArticleId IdType="pubmed">26528110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coldman A., Phillips N., Wilson C., et al.  Erratum: Pan-Canadian study of mammography screening and mortality from breast cancer (Journal of the National Cancer Institute (2014) 106:11 (dju261) DOI: 10.1093/jnci/dju261) Journal of the National Cancer Institute. 2015;107(1) doi: 10.1093/jnci/dju404.dju404</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/dju404</ArticleId>
            <ArticleId IdType="pubmed">25274578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Njor S., Nystrom L., Moss S., et al.  Breast cancer mortality in mammographic screening in Europe: A review of incidence-based mortality studies. Journal of Medical Screening. 2012;19(1):33–41. doi: 10.1258/jms.2012.012080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1258/jms.2012.012080</ArticleId>
            <ArticleId IdType="pubmed">22972809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rick A., Cammie B., Burke A., et al.  Breast Cancer Facts &amp; Figures 2013-2014. American Cancer Society. 2014;38</Citation>
        </Reference>
        <Reference>
          <Citation>Lee S. K., Bae S. Y., Lee J. H., et al.  Distinguishing low-risk luminal a breast cancer subtypes with Ki-67 and p53 is more predictive of long-term survival. PLoS ONE. 2015;10(8) doi: 10.1371/journal.pone.0124658.e0124658</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0124658</ArticleId>
            <ArticleId IdType="pmc">PMC4524613</ArticleId>
            <ArticleId IdType="pubmed">26241661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran B., Bedard P. L. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Research. 2011;13(6, article no. 221) doi: 10.1186/bcr2904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr2904</ArticleId>
            <ArticleId IdType="pmc">PMC3326541</ArticleId>
            <ArticleId IdType="pubmed">22217398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marmé F., Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care. 2015;10(3):159–166. doi: 10.1159/000433622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000433622</ArticleId>
            <ArticleId IdType="pmc">PMC4569194</ArticleId>
            <ArticleId IdType="pubmed">26557820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S. G., Li L. Targeted therapy in HER2-positive breast cancer. Biomedical Reports. 2013;1(4):499–505. doi: 10.3892/br.2013.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/br.2013.95</ArticleId>
            <ArticleId IdType="pmc">PMC3917005</ArticleId>
            <ArticleId IdType="pubmed">24648975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellström M., Phng L., Gerhardt H. VEGF and Notch Signaling. Cell Adhesion &amp; Migration. 2014;1(3):133–136. doi: 10.4161/cam.1.3.4978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cam.1.3.4978</ArticleId>
            <ArticleId IdType="pmc">PMC2634014</ArticleId>
            <ArticleId IdType="pubmed">19262131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene. 2008;27(38):5132–5137. doi: 10.1038/onc.2008.227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2008.227</ArticleId>
            <ArticleId IdType="pmc">PMC3893692</ArticleId>
            <ArticleId IdType="pubmed">18758482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerhardt H., Golding M., Fruttiger M., et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. The Journal of Cell Biology. 2003;161(6):1163–1177. doi: 10.1083/jcb.200302047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200302047</ArticleId>
            <ArticleId IdType="pmc">PMC2172999</ArticleId>
            <ArticleId IdType="pubmed">12810700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco R., Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harbor Perspectives in Medicine. 2013;3(1) doi: 10.1101/cshperspect.a006569.a006569</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a006569</ArticleId>
            <ArticleId IdType="pmc">PMC3530037</ArticleId>
            <ArticleId IdType="pubmed">23085847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aster J. C. In brief: Notch signalling in health and disease. The Journal of Pathology. 2014;232(1):1–3. doi: 10.1002/path.4291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.4291</ArticleId>
            <ArticleId IdType="pubmed">24122372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P., Yan X., Chen Y., Yang Z., Han H. Notch signaling in blood vessels: From morphogenesis to homeostasis. Science China Life Sciences. 2014;57(8):774–780. doi: 10.1007/s11427-014-4716-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11427-014-4716-0</ArticleId>
            <ArticleId IdType="pubmed">25104449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capaccione K. M., Pine S. R. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34(7):1420–1430. doi: 10.1093/carcin/bgt127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgt127</ArticleId>
            <ArticleId IdType="pmc">PMC3697894</ArticleId>
            <ArticleId IdType="pubmed">23585460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giancotti F. G. Deregulation of cell signaling in cancer. FEBS Letters. 2014;588(16):2558–2570. doi: 10.1016/j.febslet.2014.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2014.02.005</ArticleId>
            <ArticleId IdType="pmc">PMC4111980</ArticleId>
            <ArticleId IdType="pubmed">24561200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan X., Wu H., Xu H. X., et al.  Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Letters. 2015;369(1):20–27. doi: 10.1016/j.canlet.2015.07.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2015.07.048</ArticleId>
            <ArticleId IdType="pubmed">26341688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kontomanolis E., Panteliadou M., Giatromanolaki A., et al.  Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: Correlation with metastasis. Medical Oncology. 2014;31(5)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24696220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shutter J. R., Scully S., Fan W., et al.  D114, a novel Notch ligand expressed in arterial endothelium. Genes &amp; Development. 2000;14(11):1313–1318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316657</ArticleId>
            <ArticleId IdType="pubmed">10837024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pugh C. W., Ratcliffe P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine. 2003;9(6):677–684. doi: 10.1038/nm0603-677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0603-677</ArticleId>
            <ArticleId IdType="pubmed">12778166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benedito R., Roca C., Sörensen I., et al.  The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis. Cell. 2009;137(6):1124–1135. doi: 10.1016/j.cell.2009.03.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.03.025</ArticleId>
            <ArticleId IdType="pubmed">19524514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eilken H. M., Adams R. H. Dynamics of endothelial cell behavior in sprouting angiogenesis. Current Opinion in Cell Biology. 2010;22(5):617–625. doi: 10.1016/j.ceb.2010.08.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2010.08.010</ArticleId>
            <ArticleId IdType="pubmed">20817428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology. 2002;20(21):4368–4380. doi: 10.1200/JCO.2002.10.088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2002.10.088</ArticleId>
            <ArticleId IdType="pubmed">12409337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodivala-Dilke K. M., Reynolds A. R., Reynolds L. E. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell and Tissue Research. 2003;314(1):131–144. doi: 10.1007/s00441-003-0774-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-003-0774-5</ArticleId>
            <ArticleId IdType="pubmed">13680353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribatti D., Crivellato E. Sprouting angiogenesisquot, a reappraisal. Developmental Biology. 2012;37:157–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23031691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suchting S., Eichmann A. Jagged Gives Endothelial Tip Cells an Edge. Cell. 2009;137(6):988–990. doi: 10.1016/j.cell.2009.05.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.05.024</ArticleId>
            <ArticleId IdType="pubmed">19524499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siemerink M. J., Klaassen I., van Noorden C. J. F., Schlingemann R. O. Endothelial Tip Cells in Ocular Angiogenesis: Potential Target for Anti-Angiogenesis Therapy. Journal of Histochemistry &amp; Cytochemistry. 2013;61(2):101–115. doi: 10.1369/0022155412467635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1369/0022155412467635</ArticleId>
            <ArticleId IdType="pmc">PMC3636692</ArticleId>
            <ArticleId IdType="pubmed">23092791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang T. P., Gazdar A. F., Virmani A. K., et al.  Chromosome 19 Translocation, Overexpression of Notch3, and Human Lung Cancer. JNCI Journal of the National Cancer Institute. 2000;92(16):1355–1357. doi: 10.1093/jnci/92.16.1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/92.16.1355</ArticleId>
            <ArticleId IdType="pubmed">10944559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallahan A. R., Pritchard J. I., Hansen S., et al.  The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Research. 2004;64(21):7794–7800. doi: 10.1158/0008-5472.can-04-1813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-04-1813</ArticleId>
            <ArticleId IdType="pubmed">15520185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curry C. L., Reed L. L., Golde T. E., Miele L., Nickoloff B. J., Foreman K. E. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005;24(42):6333–6344. doi: 10.1038/sj.onc.1208783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1208783</ArticleId>
            <ArticleId IdType="pubmed">15940249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedogni B., Warneke J. A., Nickoloff B. J., Giaccia A. J., Powell M. B. Notch1 is an effector of Akt and hypoxia in melanoma development. The Journal of Clinical Investigation. 2008;118(11):3660–3670. doi: 10.1172/JCI36157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI36157</ArticleId>
            <ArticleId IdType="pmc">PMC2567838</ArticleId>
            <ArticleId IdType="pubmed">18924608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pece S., Serresi M., Santolini E., et al.  Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. The Journal of Cell Biology. 2004;167(2):215–221. doi: 10.1083/jcb.200406140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200406140</ArticleId>
            <ArticleId IdType="pmc">PMC2172557</ArticleId>
            <ArticleId IdType="pubmed">15492044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stylianou S., Clarke R. B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Research. 2006;66(3):1517–1525. doi: 10.1158/0008-5472.can-05-3054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-05-3054</ArticleId>
            <ArticleId IdType="pubmed">16452208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittal S., Subramanyam D., Dey D., Kumar R. V., Rangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Molecular Cancer. 2009;8, article 128 doi: 10.1186/1476-4598-8-128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-8-128</ArticleId>
            <ArticleId IdType="pmc">PMC2809056</ArticleId>
            <ArticleId IdType="pubmed">20030805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reedijk M., Odorcic S., Chang L., et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research. 2005;65(18):8530–8537. doi: 10.1158/0008-5472.can-05-1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-05-1069</ArticleId>
            <ArticleId IdType="pubmed">16166334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dievart A., Beaulieu N., Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18(44):5973–5981. doi: 10.1038/sj.onc.1202991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1202991</ArticleId>
            <ArticleId IdType="pubmed">10557086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dontu G., Jackson K. W., McNicholas E., Kawamura M. J., Abdallah W. M., Wicha M. S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Research. 2004;6(6):R605–R615. doi: 10.1186/bcr920.  http://www.ncbi.nlm.nih.gov.wncln.wncln.org/pubmed/?term=Role+of+Notch+signaling+in+cell-fate+determination+of+human+mammary+stem/progenitor+cells.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr920</ArticleId>
            <ArticleId IdType="pmc">PMC1064073</ArticleId>
            <ArticleId IdType="pubmed">15535842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J. T., Li M., Nakayama K., et al.  Notch3 gene amplification in ovarian cancer. Cancer Research. 2006;66(12):6312–6318. doi: 10.1158/0008-5472.CAN-05-3610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3610</ArticleId>
            <ArticleId IdType="pubmed">16778208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallahan D., Jhappan C., Robinson G., et al.  Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Research. 1996;56(8):1775–1785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8620493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callahan R., Egan S. E. Notch signaling in mammary development and oncogenesis. Journal of Mammary Gland Biology and Neoplasia. 2004;9(2):145–163. doi: 10.1023/B:JOMG.0000037159.63644.81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/B:JOMG.0000037159.63644.81</ArticleId>
            <ArticleId IdType="pubmed">15300010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parr C., Watkins G., Jiang W. G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. International Journal of Molecular Medicine. 2004;14(5):779–786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15492845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu C., Diévart A., Lupien M., Calvo E., Tremblay G., Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. The American Journal of Pathology. 2006;168(3):973–990. doi: 10.2353/ajpath.2006.050416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2006.050416</ArticleId>
            <ArticleId IdType="pmc">PMC1606519</ArticleId>
            <ArticleId IdType="pubmed">16507912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klinakis A., Szaboks M., Politi K., Kiaris H., Artavanis-Tsakonas S., Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proceedings of the National Acadamy of Sciences of the United States of America. 2006;103(24):9262–9267. doi: 10.1073/pnas.0603371103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0603371103</ArticleId>
            <ArticleId IdType="pmc">PMC1570422</ArticleId>
            <ArticleId IdType="pubmed">16751266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michalides R., van Nie R., Nusse R., Hynes N. E., Groner B. Mammary tumor induction loci in GR and DBAf mice contain one provirus of the mouse mammary tumor virus. Cell. 1981;23(1):165–173. doi: 10.1016/0092-8674(81)90281-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(81)90281-6</ArticleId>
            <ArticleId IdType="pubmed">6260372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallahan D., Callahan R. Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. Journal of Virology. 1987;61:66–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC255203</ArticleId>
            <ArticleId IdType="pubmed">3023708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jhappan C., Gallahan D., Stahle C., et al.  Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes &amp; Development. 1992;6(3):345–355. doi: 10.1101/gad.6.3.345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.6.3.345</ArticleId>
            <ArticleId IdType="pubmed">1372276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins J., Blondel B. J., Gallahan D., Callahan R. Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. Journal of Virology. 1992;66:2594–2599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC289064</ArticleId>
            <ArticleId IdType="pubmed">1312643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imatani A., Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene. 2000;19(2):223–231. doi: 10.1038/sj.onc.1203295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1203295</ArticleId>
            <ArticleId IdType="pubmed">10645000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlandi R., Troglio F., Casalini P., et al.  SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro. Cancer Research. 2002;62(2):567–574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11809711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boras-Granic K., Wysolmerski J. J. Wnt signaling in breast organogenesis. Organogenesis. 2008;4(2):116–122. doi: 10.4161/org.4.2.5858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/org.4.2.5858</ArticleId>
            <ArticleId IdType="pmc">PMC2634257</ArticleId>
            <ArticleId IdType="pubmed">19279723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayyanan A., Civenni G., Ciarloni L., et al.  Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proceedings of the National Acadamy of Sciences of the United States of America. 2006;103(10):3799–3804. doi: 10.1073/pnas.0600065103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0600065103</ArticleId>
            <ArticleId IdType="pmc">PMC1450156</ArticleId>
            <ArticleId IdType="pubmed">16501043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prosperi J. R., Goss K. H. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Current Drug Targets. 2010;1:p. pp.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20545611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nusse R. Wnt signaling in disease and in development. Cell Research. 2005;15(1):28–32. doi: 10.1038/sj.cr.7290260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cr.7290260</ArticleId>
            <ArticleId IdType="pubmed">15686623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diessner J., Wischnewsky M., Blettner M., et al.  Do patients with luminal a breast cancer profit from adjuvant systemic therapy? A retrospective multicenter study. PLoS ONE. 2016;11(12) doi: 10.1371/journal.pone.0168730.e0168730</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0168730</ArticleId>
            <ArticleId IdType="pmc">PMC5167411</ArticleId>
            <ArticleId IdType="pubmed">27992550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haughian J. M., Pinto M. P., Harrell J. C., et al.  Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Acadamy of Sciences of the United States of America. 2012;109(8):2742–2747. doi: 10.1073/pnas.1106509108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1106509108</ArticleId>
            <ArticleId IdType="pmc">PMC3287001</ArticleId>
            <ArticleId IdType="pubmed">21969591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dou X., Liang Y., Lin H., et al.  Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α. Theranostics. 2017;7(16):4041–4056. doi: 10.7150/thno.19989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.19989</ArticleId>
            <ArticleId IdType="pmc">PMC5667424</ArticleId>
            <ArticleId IdType="pubmed">29109797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Touplikioti P. Expression of Notch Receptors in Primary Breast Cancer and Correlation with Pathological Features. Clinical &amp; Experimental Pharmacology. 2012;02(01) doi: 10.4172/2161-1459.1000109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2161-1459.1000109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Speiser J., Foreman K., Drinka E., et al.  Notch-1 and notch-4 biomarker expression in triple-negative breast cancer. International Journal of Surgical Pathology. 2012;20(2):139–145. doi: 10.1177/1066896911427035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1066896911427035</ArticleId>
            <ArticleId IdType="pubmed">22084425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickson B. C., Mulligan A. M., Zhang H., et al.  High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Modern Pathology. 2007;20(6):685–693. doi: 10.1038/modpathol.3800785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.3800785</ArticleId>
            <ArticleId IdType="pubmed">17507991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colbert L. S., Wilson K., Kim S., et al.  NILCO biomarkers in breast cancer from Chinese patients. BMC Cancer. 2014;14(1, article no. 249) doi: 10.1186/1471-2407-14-249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-14-249</ArticleId>
            <ArticleId IdType="pmc">PMC4101832</ArticleId>
            <ArticleId IdType="pubmed">24716804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K., Zhang Q., Li D., et al.  PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor. Clinical Cancer Research. 2015;21(6):1487–1496. doi: 10.1158/1078-0432.ccr-14-1348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-14-1348</ArticleId>
            <ArticleId IdType="pubmed">25564152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boucher J. M., Peterson S. M., Urs S., Zhang C., Liaw L. The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. The Journal of Biological Chemistry. 2011;286(32):28312–28321. doi: 10.1074/jbc.M111.221945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.221945</ArticleId>
            <ArticleId IdType="pmc">PMC3151075</ArticleId>
            <ArticleId IdType="pubmed">21685392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V Soriano J., Uyttendaele H., Kitajewski J., Montesano R. Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. International Journal of Cancer. 2000;86:652–659. doi: 10.1002/(SICI)1097-0215(20000601)86:5&lt;652::AID-IJC8&gt;3.0.CO;2-V.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0215(20000601)86:5&lt;652::AID-IJC8&gt;3.0.CO;2-V</ArticleId>
            <ArticleId IdType="pubmed">10797286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellavia D., Checquolo S., Campese A. F., Felli M. P., Gulino A., Screpanti I. Notch3: From subtle structural differences to functional diversity. Oncogene. 2008;27(38):5092–5098. doi: 10.1038/onc.2008.230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2008.230</ArticleId>
            <ArticleId IdType="pubmed">18758477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girard L., Hanna Z., Beaulieu N., et al.  Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTV(D)/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes &amp; Development. 1996;10(15):1930–1944. doi: 10.1101/gad.10.15.1930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.10.15.1930</ArticleId>
            <ArticleId IdType="pubmed">8756350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uyttendaele H., Soriano J. V., Montesano R., Kitajewski J. Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Developmental Biology. 1998;196(2):204–217. doi: 10.1006/dbio.1998.8863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/dbio.1998.8863</ArticleId>
            <ArticleId IdType="pubmed">9576833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melchor L., Smalley M. J. Highway to heaven: Mammary gland development and differentiation. Breast Cancer Research. 2008;10(5, article no. 305) doi: 10.1186/bcr2147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr2147</ArticleId>
            <ArticleId IdType="pmc">PMC2614513</ArticleId>
            <ArticleId IdType="pubmed">18947364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi N., Oyama T., Ito E., et al.  NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Research. 2008;68(6):1881–1888. doi: 10.1158/0008-5472.CAN-07-1597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-1597</ArticleId>
            <ArticleId IdType="pubmed">18339869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callahan R., Raafat A. Notch Signaling in Mammary Gland Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia. 2001;6(1):23–36. doi: 10.1023/A:1009512414430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1009512414430</ArticleId>
            <ArticleId IdType="pubmed">11467450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Neill C. F., Urs S., Cinelli C., et al.  Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. The American Journal of Pathology. 2007;171(3):1023–1036. doi: 10.2353/ajpath.2007.061029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2007.061029</ArticleId>
            <ArticleId IdType="pmc">PMC1959488</ArticleId>
            <ArticleId IdType="pubmed">17675579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundaram M. V. The love-hate relationship between Ras and Notch. Genes &amp; Development. 2005;19(16):1825–1839. doi: 10.1101/gad.1330605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1330605</ArticleId>
            <ArticleId IdType="pubmed">16103211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beer L. A., Tang H.-Y., Sriswasdi S., Barnhart K. T., Speicher D. W. Systematic discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling coupled with label-free quantitation. Journal of Proteome Research. 2011;10(3):1126–1138. doi: 10.1021/pr1008866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr1008866</ArticleId>
            <ArticleId IdType="pmc">PMC3048922</ArticleId>
            <ArticleId IdType="pubmed">21142075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farnie G., Clarke R. B., Spence K., et al.  Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. Journal of the National Cancer Institute. 2007;99(8):616–627. doi: 10.1093/jnci/djk133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djk133</ArticleId>
            <ArticleId IdType="pubmed">17440163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jubb A. M., Soilleux E. J., Turley H., et al.  Expression of vascular Notch ligand delta-like 4 and inflammatory markers in breast cancer. The American Journal of Pathology. 2010;176(4):2019–2028. doi: 10.2353/ajpath.2010.090908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2010.090908</ArticleId>
            <ArticleId IdType="pmc">PMC2843489</ArticleId>
            <ArticleId IdType="pubmed">20167860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa M. J., Wu X., Cuervo H., et al.  Notch4 is required for tumor onset and perfusion. Vascular Cell. 2013;5(1):p. 7. doi: 10.1186/2045-824X-5-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2045-824X-5-7</ArticleId>
            <ArticleId IdType="pmc">PMC3644271</ArticleId>
            <ArticleId IdType="pubmed">23601498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weijzen S., Rizzo P., Braid M., et al.  Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Medicine. 2002;8(9):979–986. doi: 10.1038/nm754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm754</ArticleId>
            <ArticleId IdType="pubmed">12185362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein L., Ross R. K. Endogenous hormones and breast cancer risk. Epidemiologic Reviews. 1993;15(1):48–65. doi: 10.1093/oxfordjournals.epirev.a036116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.epirev.a036116</ArticleId>
            <ArticleId IdType="pubmed">8405212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares R., Balogh G., Guo S., Gärtner F., Russo J., Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Molecular Endocrinology. 2004;18(9):2333–2343. doi: 10.1210/me.2003-0362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/me.2003-0362</ArticleId>
            <ArticleId IdType="pubmed">15192074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calaf G., Roy D. Cell adhesion proteins altered by 17β estradiol and parathion in breast epithelial cells. Oncology Reports. 2008 doi: 10.3892/or.19.1.165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.19.1.165</ArticleId>
            <ArticleId IdType="pubmed">18097591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzo P., Miao H., D'Souza G., et al.  Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research. 2008;68(13):5226–5235. doi: 10.1158/0008-5472.can-07-5744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-07-5744</ArticleId>
            <ArticleId IdType="pmc">PMC4445363</ArticleId>
            <ArticleId IdType="pubmed">18593923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao L., Rizzo P., Osipo C., et al.  Notch-1 activates estrogen receptor-α-dependent transcription via IKKα in breast cancer cells. Oncogene. 2010;29(2):201–213. doi: 10.1038/onc.2009.323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2009.323</ArticleId>
            <ArticleId IdType="pmc">PMC4976641</ArticleId>
            <ArticleId IdType="pubmed">19838210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D. The Notch ligand Jagged1 as a target for anti-tumor therapy. Frontiers in Oncology. 2014;4 doi: 10.3389/fonc.2014.00254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2014.00254</ArticleId>
            <ArticleId IdType="pmc">PMC4174884</ArticleId>
            <ArticleId IdType="pubmed">25309874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Politi K., Feirt N., Kitajewski J. Notch in mammary gland development and breast cancer. Seminars in Cancer Biology. 2004;14(5):341–347. doi: 10.1016/j.semcancer.2004.04.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2004.04.013</ArticleId>
            <ArticleId IdType="pubmed">15288259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aste-Amézaga M., Zhang N., Lineberger J. E., et al.  Characterization of notch1 antibodies that inhibit signaling of both normal and mutated notch1 receptors. PLoS ONE. 2010;5(2) doi: 10.1371/journal.pone.0009094.e9094</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0009094</ArticleId>
            <ArticleId IdType="pmc">PMC2817004</ArticleId>
            <ArticleId IdType="pubmed">20161710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Cain-Hom C., Choy L., et al.  Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052–1057. doi: 10.1038/nature08878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08878</ArticleId>
            <ArticleId IdType="pubmed">20393564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K., Li Y., Wu W., et al.  Modulation of notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. The Journal of Biological Chemistry. 2008;283(12):8046–8054. doi: 10.1074/jbc.m800170200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.m800170200</ArticleId>
            <ArticleId IdType="pubmed">18182388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arcaroli J. J., Dasari A., Messersmith W. A., Jimeno A. 
γ-secretase inhibitors in solid tumor malignancies. Drugs of the Future. 2011;36(9):677–689. doi: 10.1358/dof.2011.036.09.1678340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1358/dof.2011.036.09.1678340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pannuti A., Foreman K., Rizzo P., et al.  Targeting Notch to target cancer stem cells. Clinical Cancer Research. 2010;16(12):3141–3152. doi: 10.1158/1078-0432.CCR-09-2823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-2823</ArticleId>
            <ArticleId IdType="pmc">PMC3008160</ArticleId>
            <ArticleId IdType="pubmed">20530696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epenetos A., Kousparou C., Stylianou S.  Inhibition of Notch signaling for the treatment of human carcinomas. Waverly Press; 2009. </Citation>
        </Reference>
        <Reference>
          <Citation>Moellering R. E., Cornejo M., Davis T. N., et al.  Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462(7270):182–188. doi: 10.1038/nature08543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08543</ArticleId>
            <ArticleId IdType="pmc">PMC2951323</ArticleId>
            <ArticleId IdType="pubmed">19907488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J., Ma I., Hendzel M. J., Allalunis-Turner J. The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition. Breast Cancer Research. 2009;11(4, article no. R57) doi: 10.1186/bcr2347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr2347</ArticleId>
            <ArticleId IdType="pmc">PMC2750119</ArticleId>
            <ArticleId IdType="pubmed">19660128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamaeva V., Niemi R., Beck M., et al.  Inhibiting notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying γ-secretase inhibitors. Molecular Therapy. 2016;24(5):926–936. doi: 10.1038/mt.2016.42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2016.42</ArticleId>
            <ArticleId IdType="pmc">PMC4881775</ArticleId>
            <ArticleId IdType="pubmed">26916284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z., Turkoz A., Jackson E. N., et al.  Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. The Journal of Clinical Investigation. 2011;121(2):800–808. doi: 10.1172/JCI43114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI43114</ArticleId>
            <ArticleId IdType="pmc">PMC3026721</ArticleId>
            <ArticleId IdType="pubmed">21266774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan M., Callahan C. A., Beyer J. C., et al.  Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463(7282):E6–E7. doi: 10.1038/nature08751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08751</ArticleId>
            <ArticleId IdType="pubmed">20147986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meurette O., Stylianou S., Rock R., Collu G. M., Gilmore A. P., Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Research. 2009;69(12):5015–5022. doi: 10.1158/0008-5472.CAN-08-3478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3478</ArticleId>
            <ArticleId IdType="pubmed">19491273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondratyev M., Kreso A., Hallett R. M., et al.  Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2012;31(1):93–103. doi: 10.1038/onc.2011.212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2011.212</ArticleId>
            <ArticleId IdType="pubmed">21666715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osipo C., Patel P., Rizzo P., et al.  ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene. 2008;27(37):5019–5032. doi: 10.1038/onc.2008.149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2008.149</ArticleId>
            <ArticleId IdType="pubmed">18469855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandya K., Meeke K., Clementz A. G., et al.  Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer. 2011;105(6):796–806. doi: 10.1038/bjc.2011.321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.321</ArticleId>
            <ArticleId IdType="pmc">PMC3171020</ArticleId>
            <ArticleId IdType="pubmed">21847123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simões B., O’Brien C., Eyre R., et al.  Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Reports. 2015;12(12):1968–1977. doi: 10.1016/j.celrep.2015.08.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.08.050</ArticleId>
            <ArticleId IdType="pmc">PMC4594158</ArticleId>
            <ArticleId IdType="pubmed">26387946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartwig F. P., Nedel F., Collares T., Tarquinio S. B. C., Nör J. E., Demarco F. F. Oncogenic somatic events in tissue-specific stem cells: A role in cancer recurrence? Ageing Research Reviews. 2014;13(1):100–106. doi: 10.1016/j.arr.2013.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2013.12.004</ArticleId>
            <ArticleId IdType="pubmed">24374269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorden B. H., Kim J.-H., Sarver A. L., et al.  Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. The American Journal of Pathology. 2014;184(4):985–995. doi: 10.1016/j.ajpath.2013.12.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2013.12.025</ArticleId>
            <ArticleId IdType="pmc">PMC3969990</ArticleId>
            <ArticleId IdType="pubmed">24525151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R.-A., Li Z.-S., Zhang H.-Z., et al.  Invasive cancers are not necessarily from preformed in situ tumours - an alternative way of carcinogenesis from misplaced stem cells. Journal of Cellular and Molecular Medicine. 2013;17(7):921–926. doi: 10.1111/jcmm.12078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12078</ArticleId>
            <ArticleId IdType="pmc">PMC3822897</ArticleId>
            <ArticleId IdType="pubmed">23741988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponti D., Costa A., Zaffaroni N., et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Research. 2005;65(13):5506–5511. doi: 10.1158/0008-5472.can-05-0626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-05-0626</ArticleId>
            <ArticleId IdType="pubmed">15994920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright M. H., Calcagno A., Salcido C. D., Carlson M. D., Ambudkar S. V., Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Research. 2008;10, article R10 doi: 10.1186/bcr1855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr1855</ArticleId>
            <ArticleId IdType="pmc">PMC2374965</ArticleId>
            <ArticleId IdType="pubmed">18241344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrera-Gayol A., Jothy S. CD44 modulates HS578T human breast cancer cell adhesion, migration, and invasiveness. Experimental and Molecular Pathology. 1999;66(1):99–108. doi: 10.1006/exmp.1999.2236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/exmp.1999.2236</ArticleId>
            <ArticleId IdType="pubmed">10331969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rangaswami H., Bulbule A., Kundu G. C. Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biology. 2006;16(2):79–87. doi: 10.1016/j.tcb.2005.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2005.12.005</ArticleId>
            <ArticleId IdType="pubmed">16406521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schabath H., Runz S., Joumaa S., Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. Journal of Cell Science. 2006;119(2):314–325. doi: 10.1242/jcs.02741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.02741</ArticleId>
            <ArticleId IdType="pubmed">16390867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balicki D. Moving Forward in Human Mammary Stem Cell Biology and Breast Cancer Prognostication Using ALDH1. Cell Stem Cell. 2007;1(5):485–487. doi: 10.1016/j.stem.2007.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2007.10.015</ArticleId>
            <ArticleId IdType="pubmed">18938743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Ejeh F., Smart C. E., Morrison B. J., et al.  Breast cancer stem cells: Treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32(5):650–658. doi: 10.1093/carcin/bgr028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgr028</ArticleId>
            <ArticleId IdType="pubmed">21310941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karamboulas C., Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochimica et Biophysica Acta (BBA) - General Subjects. 2013;1830(2):2481–2495. doi: 10.1016/j.bbagen.2012.11.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2012.11.008</ArticleId>
            <ArticleId IdType="pubmed">23196196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñoz P., Iliou M. S., Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Molecular Oncology. 2012;6(6):620–636. doi: 10.1016/j.molonc.2012.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2012.10.006</ArticleId>
            <ArticleId IdType="pmc">PMC5528346</ArticleId>
            <ArticleId IdType="pubmed">23141800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Fischer W. H., Gill G. N. Regulation of the ERBB-2 promoter by RBPJκ and NOTCH. The Journal of Biological Chemistry. 1997;272(22):14110–14114. doi: 10.1074/jbc.272.22.14110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.272.22.14110</ArticleId>
            <ArticleId IdType="pubmed">9162037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnifico A., Albano L., Campaner S., et al.  Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clinical Cancer Research. 2009;15(6):2010–2021. doi: 10.1158/1078-0432.ccr-08-1327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-08-1327</ArticleId>
            <ArticleId IdType="pubmed">19276287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dontu G., Jackson K. W., McNicholas E., Kawamura M. J., Abdallah W. M., Wicha M. S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Research. 2004;6(6):R605–R615. doi: 10.1186/bcr920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr920</ArticleId>
            <ArticleId IdType="pmc">PMC1064073</ArticleId>
            <ArticleId IdType="pubmed">15535842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farnie G., Clarke R. B. Mammary stem cells and breast cancer—role of Notch signalling. Stem Cell Reviews and Reports. 2007;3(2):169–175. doi: 10.1007/s12015-007-0023-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-007-0023-5</ArticleId>
            <ArticleId IdType="pubmed">17873349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison H., Simões B. M., Rogerson L., Howell S. J., Landberg G., Clarke R. B. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Research. 2013;15(2, article R21) doi: 10.1186/bcr3396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr3396</ArticleId>
            <ArticleId IdType="pmc">PMC3672803</ArticleId>
            <ArticleId IdType="pubmed">23497505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison H., Farnie G., Howell S. J., et al.  Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Research. 2010;70(2):709–718. doi: 10.1158/0008-5472.can-09-1681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-09-1681</ArticleId>
            <ArticleId IdType="pmc">PMC3442245</ArticleId>
            <ArticleId IdType="pubmed">20068161</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
